NIKKEI 225
38,274.05 -131.61 (-0.34%) HANG SENG
17,763.03 +16.12 (+0.09%) CRUDE OIL
81.04 -0.89 (-1.09%) GOLD FUTURES
2,299.30 -3.60 (-0.16%) DOW
37,815.92 -570.17 (-1.49%) Bitcoin GBP
47,819.61 -3,049.16 (-5.99%)
NVO Jan 2025 67.500 call
| Previous close | 41.50 |
| Open | 41.50 |
| Bid | 56.50 |
| Ask | 61.00 |
| Strike | 67.50 |
| Expiry date | 2025-01-17 |
| Day's range | 41.50 - 41.50 |
| Contract range | N/A |
| Volume | |
| Open interest | 24 |
Yahoo FinanceEli Lilly reports $2 billion from Mounjaro, Zepbound in Q1 2024
Eli Lilly missed on total sales in the first quarter, but its GLP-1 drugs helped boost sales by 26% over those in Q1 2023.
Investor's Business DailyIBD Stock Of The Day Eli Lilly Surges After Weight-Loss Drug Obliterates Sales Views
Eli Lilly stock jumped Tuesday despite a mixed first-quarter report, after sales of weight-loss drug Zepbound obliterated expectations.
BloombergOzempic Maker Novo Nordisk Has Denmark’s Economy Hooked
(Bloomberg) -- There is no escaping Ozempic and Wegovy. The diabetes and obesity drugs are a global phenomenon. They’ve won over the rich and famous, generated billions in sales and blown open a new market for weight loss drugs, which Goldman Sachs estimates will reach $100 billion a year by 2030.Most Read from BloombergTesla Axes Most of Supercharger Team in Blow to Other AutomakersTraders Expect Biggest Fed-Day Move in S&P Since 2023, Citi SaysWall Street Hit by Fed Jitters to Close Wild April
